Trial Update November 13, 2026

Phase 3 Trial Referencing Semaglutide in Type 2 Diabetes Completes

A clinical trial involving semaglutide as a comparator was updated on November 13, 2026. The study, titled "A Study of BGM0504 in Participants With Type 2 Diabetes," is registered under identifier NCT06716216. According to its ClinicalTrials.gov record, the trial is a Phase 3 study and its status is listed as completed.

The trial's title indicates it was conducted in participants with type 2 diabetes. No specific results, outcomes, or efficacy data were included in this update. The listing reflects only the trial's phase and current status as recorded on the referenced date.

This update does not state whether results have been posted or published. No safety or efficacy conclusions can be drawn from a status update alone. Readers interested in the full trial design, enrollment criteria, and sponsor details can consult the ClinicalTrials.gov registration directly.

For additional background on this compound, readers can consult the semaglutide overview page.

See the full semaglutide overview

Source: https://clinicaltrials.gov/study/NCT06716216